Boehringer Ingelheim Embeds OpenProtein.AI in 3 Drug Programs After 2025 Research-Pipeline Integration
Updated
Updated · Futura · Jul 5
Boehringer Ingelheim Embeds OpenProtein.AI in 3 Drug Programs After 2025 Research-Pipeline Integration
1 articles · Updated · Futura · Jul 5
Summary
Boehringer Ingelheim has expanded its use of OpenProtein.AI from a 2025 research-pipeline integration to direct deployment in therapeutic protein engineering for oncology, immunology and inflammatory diseases.
The platform is designed to let lab scientists upload data, train models, generate protein variants and validate results in a web browser, removing the need for specialized GPUs, custom software stacks and deep machine-learning expertise.
Its PoET architecture can work with 30x less experimental data and uses a 182 million-parameter model to screen digital protein candidates before wet-lab testing, cutting manual trial-and-error cycles.
The deal underscores a broader TechBio shift toward treating DNA and proteins as programmable languages, alongside larger-scale models such as Evo2, which was trained on 9.3 trillion nucleotides from 128,000 genomes.
OpenProtein.AI's PoET platform is a major advancement in protein engineering, using generative AI to speed up the discovery and optimization of new proteins. It gives biotechnology and pharmaceutical companies a ready-to-use AI infrastructure that transforms how proteins are designed and developed. With powerful generative AI features, users can customize their protein designs and adapt the platform for specific needs. Features like prompt customization let users define the evolutionary context for their designs, making the platform flexible and highly specialized for different applications.